Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Maintaining Privacy and Confidentiality of Volunteers – V 2.0

Posted on By

BA-BE Studies: SOP for Maintaining Privacy and Confidentiality of Volunteers – V 2.0

Standard Operating Procedure for Maintaining Privacy and Confidentiality of Volunteers in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/104/2025
Supersedes SOP/BA-BE/104/2022
Page No. Page 1 of 9
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To establish a standardized procedure for maintaining the privacy and confidentiality of volunteer identity and data during all phases of Bioavailability/Bioequivalence (BA/BE) studies in compliance with ICH GCP, Schedule Y, and national ethical standards.

2. Scope

This SOP is applicable to all clinical trial staff, including investigators, study coordinators, nurses, data management personnel, and archivists who have

access to identifiable volunteer data at the clinical research facility.

3. Responsibilities

  • Principal Investigator (PI): Ensures all staff are trained on confidentiality requirements and protocols.
  • Clinical Research Coordinator (CRC): Ensures all volunteer forms and records are coded and handled securely.
  • QA Officer: Audits and verifies compliance with confidentiality standards.
  • IT/Data Manager: Manages electronic data access controls and password-protected systems.
See also  BA-BE Studies: SOP for Protocol and SAP (Statistical Analysis Plan) Integration - V 2.0

4. Accountability

The PI and Head of Quality are accountable for ensuring that all study-related volunteer information is protected from unauthorized access, use, disclosure, or loss.

5. Procedure

5.1 Volunteer Coding and Identity Protection

  1. Assign a unique Volunteer ID (e.g., VOL-104-001) at the time of enrollment.
  2. Ensure personal identifiers (name, address, contact) are recorded only in the screening log (Annexure-1) maintained under lock and key.
  3. CRFs and study documents must refer to the volunteer only by their assigned ID.

5.2 Secure Storage of Physical Records

  1. Keep all identifiable documents in locked cabinets within an access-controlled archive room.
  2. Access must be granted only to authorized personnel listed in Annexure-2: Access Control Log.

5.3 Electronic Data Protection

  1. Store volunteer data in password-protected systems with access restricted to designated users.
  2. Enable audit trails to track all data access and modifications.
  3. Backups must be encrypted and stored separately as per the data policy.
See also  BA-BE Studies: SOP for Crossover Period Washout Management - V 2.0

5.4 Training and Confidentiality Agreements

  1. All staff handling volunteer data must:
    • Sign a Confidentiality Agreement (Annexure-3)
    • Undergo annual training on data privacy

5.5 Disclosure and Exceptions

  1. Volunteer data may be disclosed only:
    • With written consent from the subject
    • During authorized regulatory inspections or audits
  2. All disclosures must be documented in Annexure-4: Disclosure Record Log.

5.6 Disposal and Archival

  1. Archive documents with volunteer identifiers for the minimum retention period mandated by regulations (typically 5 years post-study or as per sponsor).
  2. At end of retention period, destroy documents using secure methods (shredding/incineration) and document in Annexure-5: Confidential Data Disposal Log.

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • PI: Principal Investigator
  • CRC: Clinical Research Coordinator
  • QA: Quality Assurance
  • CRF: Case Report Form

7. Documents

  1. Volunteer Screening Log – Annexure-1
  2. Access Control Log – Annexure-2
  3. Confidentiality Agreement Form – Annexure-3
  4. Disclosure Record Log – Annexure-4
  5. Confidential Data Disposal Log – Annexure-5

8. References

  • ICH E6(R2) – Good Clinical Practice
  • Indian GCP Guidelines
  • Schedule Y – Drugs and Cosmetics Rules
  • Data Protection and Privacy Bill (India)
See also  BA-BE Studies: SOP for Room Temperature Monitoring in Sample Collection Areas - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Volunteer Screening Log

Volunteer ID Full Name Contact Screening Date Enrolled
VOL-104-001 Rajesh Kumar 9876543210 10/04/2025 Yes

Annexure-2: Access Control Log

Name Designation Access Level Date Granted
Sunita Reddy Data Manager Full 05/04/2025

Annexure-3: Confidentiality Agreement Form

Employee Name Role Date Signed Signature
Ajay Verma CRC 08/04/2025 Signed

Annexure-4: Disclosure Record Log

Date Recipient Purpose Authorized By
15/04/2025 Regulatory Inspector Routine Inspection PI

Annexure-5: Confidential Data Disposal Log

Date Documents Destroyed Method Destroyed By Verified By
17/04/2025 Old CRFs (Study BE-2020) Shredding Admin QA

Revision History:

Revision Date Revision No. Details Reason Approved By
10/01/2022 1.0 Initial Release Regulatory Requirement QA Head
17/04/2025 2.0 Enhanced with electronic data controls and annexures GCP Compliance QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: API Manufacturing: SOP for Conductivity Measurement in Process Solutions – V 2.0
Next Post: Biosimilars: SOP for Genetic Stability Testing – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version